Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
Executive Summary
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.